Publicly-traded company Nektar Therapeutics (NASDAQ:NKTR) had a closing price of $37.10 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $29.55, this means that the stock is overpriced by -25.55%. In the past 52 weeks the company’s stock price has moved within the range of $11.41 to $33.67.
This particular stock’s 5-day moving average is 31.70, its 20-day moving average is 25.86 and its 100-day moving average is 22.12. Nektar Therapeutics (NKTR) currently has 157470 shares outstanding, which means that its market capitalization is $5.76B.
The Details: Nektar Therapeutics (NKTR) Financial Health
When considering a potential stock, there are multiple indicators we can take into consideration that give us an idea of the company’s financial health. Checking out a company’s profit margin, for instance, shows us how much of its net sales revenue it retains as earnings. This figure is determined by taking total income and dividing it by net sales. NKTR currently has a profit margin of -79.30%.
Seeing a company’s operating margin is useful as well, as it lets us know how much profit the company keeps – after taking into account depreciation and its operating expenses. Nektar Therapeutics (NKTR) has an operating margin of -63.20%.
What Does Wall Street Say about Company?
When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for NKTR is Moderate Buy. Out of 8 total analysts who were surveyed, 1 rated it hold, and 7 rated it a Strong Buy.
Three months ago, on the other hand, the average analyst rating for Nektar Therapeutics (NKTR) was a Buy – from a survey of 5 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, and 5 rated it a Strong Buy.
Understanding Profitability at Nektar Therapeutics (NKTR)
Checking out a public company’s Earnings per Share (EPS) is a smart way of assessing its profitability. In the most recent financial results released by Nektar Therapeutics, for the quarter ending on 2017-09-30, the company posted EPS of 0.37. The average estimate of Wall Street analysts had projected 0.18.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.32, compared to -0.28 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 9 analysts is 39.61 million – compared to $37.45 million posted in the year-ago period.